黄璨;李梦涛;王迁;赵久良;曾小峰;

• 1:中国医学科学院 北京协和医学院 北京协和医院风湿免疫科

摘要(Abstract)：

<正>肺动脉高压(pulmonary artery hypertension,PAH)是一种较为罕见的肺循环压力升高的临床综合征,其发病率为5~15/百万[1-2],但不同种族分布有差异,即使积极治疗,致死率仍较高。肺动脉高压定义为:静止时右心漂浮导管测得平均肺动脉压≥25 mm Hg,肺毛细血管楔压≤15 mm Hg(除外左心疾病相关性),且肺血管阻力>3 Wood units(mm Hg/L·min),并除

关键词(KeyWords)： 肺动脉高压;转化生长因子β;骨形成蛋白;骨形成蛋白受体2

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 黄璨;李梦涛;王迁;赵久良;曾小峰;

Email:

DOI:

参考文献(References)：

• [1]Humbert M,Sitbon O,Chaouat A,et al.Pulmonary arterial hypertension in France-Results from a national registry[J].Am J Resp Crit Care,2006,173:1023-1030.
• [2]Ling Y,Johnson MK,Kiely DG,et al.Changing demographics,epidemiology,and survival of incident pulmonary arterial hypertension results from the pulmonary hypertension registry of the United Kingdom and Ireland[J].Am J Resp Crit Care,2012,186:790-796.
• [3]Farber HW,Loscalzo J.Pulmonary arterial hypertension[J].N Engl J Med,2004,351:1655-1665.
• [4]Galie N,Simonneau G.The fifth world symposium on pulmonary hypertension[J].J Am Coll Cardiol,2013,62:D1-D3.
• [5]Preston IR.Properly diagnosing pulmonary arterial hypertension[J].Am J Cardiol,2013,111:2C-9C.
• [6]Simonneau G,Gatzoulis MA,Adatia I,et al.Updated clini-cal classification of pulmonary hypertension[J].J Am Coll Cardiol,2013,62:D34-D41.
• [7]Hoeper MM,Bogaard HJ,Condliffe R,et al.Definitions and diagnosis of pulmonary hypertension[J].J Am Coll Cardiol,2013,62:D42-D50.
• [8]Hassoun PM,Mouthon L,Barbera JA,et al.Inflammation,growth factors,and pulmonary vascular remodeling[J].J Am Coll Cardiol,2009,54:S10-S19.
• [9]Morrell NW,Adnot S,Archer SL,et al.Cellular and molecular basis of pulmonary arterial hypertension[J].J Am Coll Cardiol,2009,54:S20-S31.
• [10]Soubrier F,Chung WK,Machado R,et al.Genetics and genomics of pulmonary arterial hypertension[J].J Am Coll Cardiol,2013,62:D13-D21.
• [11]Newman JH,Trembath RC,Morse JA,et al.Genetic basis of pulmonary arterial hypertension:current understanding and future directions[J].J Am Coll Cardiol,2004,43:33S-39S.
• [12]Loyd JE.Pulmonary arterial hypertension:insights from genetic studies[J].Proc Am Thorac Soc,2011,8:154-157.
• [13]International PPHC,Lane KB,Machado RD,et al.Heterozygous germline mutations in BMPR2,encoding a TGF-beta receptor,cause familial primary pulmonary hypertension[J].Nature Genet,2000,26:81-84.
• [14]Deng Z,Morse JH,Moore KJ,et al.Familial primary pulmonary hypertension(gene PPH1)is caused by mutations in the bone morphogenetic protein receptor-Ⅱgene[J].Am J Hum Genet,2000,67:737-744.
• [15]Trembath RC.Mutations in the TGF-beta type 1 receptor,ALK1,in combined primary pulmonary hypertension and hereditary heamrrhagic lalangiectasis,implies pathway specificity[J].J Heart Lung Transplant,2001,20:175.
• [16]Morisaki H,Nakanishi N,Morisaki T.BMPR2 mutations found in Japanese patients with familial and sporadic primary pulmonary hypertension[J].Hum Mutat,2004,23:632.
• [17]Machado RD,Aldred MA,Patel B,et al.Mutations of the TGF-beta typeⅡreceptor BMPR2 in pulmonary arterial hypertension[J].Hum Mutat,2006,27:121-132.
• [18]Nicod LP.The endothelium and genetics in pulmonary arterial hypertension[J].Swiss Med,2007,137:437-442.
• [19]Nasim MT,Ogo T,Chowdhury HM,et al.Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension[J].Hum Mutat,2011,32:1385-1389.
• [20]Chaouat A,Simonneau G,Weitzenblum E,et al.Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension[J].Thorax,2004,59:446-448.
• [21]Harrison RE,Flanagan JA,Sankelo M,et al.Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia[J].J Med Genet,2003,40:865-871.
• [22]Attisano L,Wrana JL.Signal transduction by the TGF-beta superfamily[J].Science,2002,296:1646-1647.
• [23]Newman JH,Phillips JA 3rd,Loyd JE.Narrative review:the enigma of pulmonary arterial hypertension:new insights from genetic studies[J].Ann Intern Med,2008,148:278-283.
• [24]Eickelberg O,Morty RE.Transforming growth factor beta/bone morphogenic protein signaling in pulmonary arterial hypertension:remodeling revisited[J].Trends Cardiovasc Med,2007,17:263-269.
• [25]Atkinson C,Machado R,Thomson JR,et al.Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of typeⅡbone morphogenetic protein receptor[J].Circulation,2002,105:1672-1678.
• [26]Elliott CG.Genetics of pulmonary arterial hypertension:current and future implications[J].Semin Respir Critical Care Med,2005,26:365-371.
• [27]Machado RD,Pauciulo MW,Morgan NV,et al.BMPR2haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension[J].Am J Hum Genet,2001,68:92-102.
• [28]Morrell NW,Yang X,Morgan N,et al.Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1)and bone morphogenetic proteins[J].Circulation,2001,104:790-795.
• [29]Phillips JA,Stanton KC,Austin ED,et al.Synergistic heterozygosity for TGFbeta1 SNPs and BMPR2 mutations modulates the age at diagnosis and penetrance of familial pulmonary arterial hypertension[J].Genet Med,2008,10:359-365.
• [30]Austin ED,Phillips JA,Cogan JD,et al.Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension[J].Respir Res,2009,10:87.
• [31]Austin ED,Cogan JD,Hamid R,et al.Alterations in oestrogen metabolism:implications for higher penetrance of familial pulmonary arterial hypertension in females[J].Eur Respir J,2009,34:1093-1099.
• [32]Rodriguez-Murillo L,Subaran R,Marathe S,et al.Novel loci interacting epistatically with bone morphogenetic protein receptor 2 cause familial pulmonary arterial hypertension[J].J Heart Lung Transpl,2010,29:174-180.
• [33]Best DH,Austin ED,Elliott CG.Genetics of pulmonary hypertension[J].Curr Opin Cardiol,2014,29:520-527.
• [34]Eddahibi S,Humbert M,Darmon M,et al.Serotonin transporter overexpression is responsible for pulmonary arterysmooth muscle hyperplasia in primary pulmonary hypertension[J].J Clin Invest,2001,108:1141-1150.
• [35]Eddahibi S,Adnot S.Anorexigen-induced pulmonary hypertension and the serotonin(5-HT)hypothesis:lessons for the future in pathogenesis[J].Respir Res,2002,3:9.
• [36]Zhang H,Xu M,Xia J.Association between serotonin transporter(SERT)gene polymorphism and idiopathic pulmonary arterial hypertension:a meta-analysis and review of the literature[J].Metabolism,2013,62:1867-1875.
• [37]Germain M,Eyries M,Girerd B,et al.Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension[J].Nat Genet,2013,45:518-521.
• [38]Ma L,Chung WK.The genetic basis of pulmonary arterial hypertension[J].Hum Genet,2014,133:471-479.
• [39]Maloney JP,Stearman RS,Tripp-Addison ML,et al.Lossof-function thrombospondin-1 mutations in familial pulmonary hypertension[J].Am J Physiol Lung Cell Mol Physiol,2012,302:L541-L554.
• [40]Katta S,Vadapalli S,Sastry BK,et al.t-plasminogen activator inhibitor-1 polymorphism in idiopathic pulmonary arterial hypertension[J].Indian J Hum Genet,2008,14:37-40.
• [41]Austin ED,Loyd JE.The genetics of pulmonary arterial hypertension[J].Circ Res,2014,115:189-202.
• [42]Habashi JP,Judge DP,Loeys BL,et al.Losartan,an AT1antagonist,prevents aortic aneurysm in a mouse model of Marfan syndrome[J].Science,2006,312:117-121.
• [43]Daniels CE,Wilkes MC,Edens M,et al.Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis[J].J Clin Invest,2004,114:1308-1316.